Suprachoroidal Administration: A Targeted Approach to Treating Retinal Diseases

This technique may allow a direct path for drugs to reach the back of the eye.

BY SHREE K. KURUP, MD; CLAUDIA G. HOOTEN, MD; AND SARA V. BRANSON, BS

Treatment of sight-threatening diseases, particularly those of the retina and choroid, poses a familiar challenge. The drug or therapeutic intervention must reach the targeted ocular tissue at the right concentration or at the appropriate frequency to produce the optimal outcome while at the same time minimizing the interaction of the drug with unintended targets. The overall goal is to optimize efficacy at the intended site of action and to reduce the side effects and complications of the drug. This balance is important, even in the local administration of drugs to the eye through topical drops, intravitreal injection, or implantation.

The unique anatomy of the eye also poses a challenge, in that the target tissues for the majority of sight-threatening conditions are located posteriorly. This requires drugs to traverse the anterior chamber or other outer structures of the eye in order to reach the targeted tissues following local administration. The dilemma in the case of corticosteroid use is how to deliver these drugs to the posterior of the eye without adversely affecting anterior tissues. Administering drugs through the suprachoroidal space of the eye provides a potential solution to this challenge.

SUPRACHOROIDAL DRUG DELIVERY

The suprachoroidal space is an approximately 30-µm thick layer forming a transition zone between the choroid and sclera. It is composed of closely packed layers of long pigmented processes derived from each tissue, and it appears to provide a pathway for uveoscleral outflow. Fluid injected into the suprachoroidal space spreads around the globe on top of the choroid, distributing through the choroid and retina. Should a drug be injected, the solution or suspension spreads in a similar manner across the choroid. In contrast, when the same drug is injected into the vitreous, the drug diffuses across all parts of the eye. The suprachoroidal space appears to provide a compartment through which drugs can flow, reducing exposure of the vitreous and anterior segment to the injected entity. Furthermore, providing a more targeted approach to accessing retinal and choroidal tissues results in a higher local concentration of drug in the posterior tissues and may allow lower doses of a drug to be administered or less frequent dosing.

At a Glance

- Administration of drug through the suprachoroidal space results in an apparent compartmentalization of drug to the posterior segment of the eye without unduly exposing the vitreous and anterior segment.
- One potential advantage for suprachoroidal delivery of corticosteroids over other intra- and periocular corticosteroid delivery methods is that it may allow lower doses or less frequent dosing than current local treatments, with potentially better efficacy and fewer adverse events.
- Suprachoroidal administration of triamcinolone acetonide has shown promising results in preclinical and early clinical studies.
The advantage of the suprachoroidal space as a potential route for drug administration has only undergone limited exploration in the treatment of ophthalmic diseases. For example, drug administration through the suprachoroidal space as a therapy for retinal disease has been studied using a surgical procedure employing the placement of long cannulas for administering drug. However, for extended or chronic therapy requiring multiple treatments, accessing the suprachoroidal space by this method or similar surgical methods is impractical. Furthermore, it is difficult to justify the risk of surgical intervention when no obvious advantage over other local therapies has been demonstrated.

Realizing the therapeutic potential of the suprachoroidal space requires an approach that allows drugs to be introduced to the space in a minimally invasive yet consistent and efficient manner. Therapeutic advantages must be demonstrated through a systematic set of preclinical and clinical studies.

**REVIEW OF RELEVANT STUDIES**

**Preclinical Studies**

In preclinical studies, triamcinolone acetonide (TA) administered through the suprachoroidal space using a proprietary microinjector (Clearside Biomedical; Figure) has shown promising potential for efficacy. In animal models, improved antiinflammatory activity was seen with suprachoroidal administration of TA at a lower dose compared with TA given by intravitreal injection or maintenance dose prednisone given orally. Studies measuring the distribution of drug in a rabbit model found higher concentrations of drug in relevant tissues (choroid and retina) and lower concentrations in nontarget areas of the eye (lens, aqueous humor) with suprachoroidal administration than with intravitreal administration. Preclinical efficacy studies in a pig model of acute uveitis found that a 0.2-mg dose of TA injected suprachoroidally was more effective than a 0.2-mg dose of TA administered intravitreally and as effective as a 2-mg intravitreal dose. These data demonstrated that a 10-fold lower dose of TA administered to the suprachoroidal space was sufficient to provide efficacy.

In a separate efficacy experiment using the same model, TA administered in the suprachoroidal space was as effective as high-dose daily oral corticosteroid treatment, one of the most commonly used methods of controlling inflammation associated with noninfectious uveitis. Injection of TA into the suprachoroidal space resulted in a significantly more rapid onset of antiinflammatory activity (day 1) than oral prednisone dosing (day 3) and produced efficacy equivalent to high-dose oral prednisone on day 3 and superior to low-dose prednisone, often used in maintenance therapy, on all study days.

In pharmacokinetic studies in rabbits, distribution of the drug over a 90-day period following a single suprachoroidal injection showed that TA was 12 times more available in the choroid and outer retina compared with distribution following intravitreal administration. In addition, although equal amounts of drug were found in

---

**Figure.** Administration of drug to the eye via the suprachoroidal space using a proprietary microinjector (Clearside Biomedical). Data from in vivo animal models and ex vivo eyes show the injected drug spreading around the eye after suprachoroidal injection.
“[T]he ability to treat retinal diseases by utilizing the suprachoroidal space to administer drugs to the choroid and retina may result in lower doses or less frequent dosing than conventional treatments...”

the neural retina, minimal levels of drug were found in the aqueous humor and in the iris and ciliary body with suprachoroidal administration compared with intravitreal injection of TA.6

Single- and repeat-dose toxicology studies in rabbits suggested that TA administered in the suprachoroidal space was tolerable and safe for a 13-week evaluation period following each administration, while systemic drug levels were low to undetectable.7,8

Clinical Trials

On the basis of this encouraging preliminary work, Clearside Biomedical initiated a clinical study to evaluate suprachoroidal administration of TA for the treatment of noninfectious uveitis. Results from a phase 1/2 study in patients with noninfectious uveitis showed improvement in best corrected visual acuity (BCVA) ranging between 1 and 5 lines (or up to 25 letters). At week 12, the average improvement in BCVA exceeded 2 lines, and at week 26 the average was close to 3 lines. No patient in the trial experienced any meaningful increase in intraocular pressure (IOP) at any time point following suprachoroidal space administration, and none were required to use IOP-lowering medications in the trial.9 These findings are encouraging in that they suggest that the adverse effects commonly associated with conventional ophthalmic use of corticosteroids (eg, increases in IOP and lens opacification) may be minimized when TA is administered through the suprachoroidal space.

Two clinical trials are currently enrolling patients to confirm the clinical potential of a proprietary formulation of triamcinolone (CLS-TA, Clearside Biomedical) as monotherapy and in combination with other agents for the treatment of eye diseases. One trial is a phase 2, randomized, masked, internally controlled, multicenter study to assess the safety and efficacy of two doses (4 mg or 0.8 mg) of CLS-TA administered to the suprachoroidal space using the microinjector for the treatment of patients with macular edema associated with noninfectious uveitis. The other is a phase 2, randomized, masked, internally controlled multicenter study to assess the safety and efficacy of suprachoroidally administered CLS-TA in combination with intravitreally injected aflibercept (Eylea, Regeneron) in patients with retinal vein occlusion. Results from these studies, expected in 2016, will provide the retina community with the most robust and systematic evidence to date of the clinical utility of pharmacologic therapy through the suprachoroidal space for treatment of retinal diseases.

CONCLUSION

In theory, and eventually in practice, the ability to treat retinal diseases by utilizing the suprachoroidal space to administer drugs to the choroid and retina may result in lower doses or less frequent dosing than conventional treatments, with equal or improved efficacy and fewer adverse effects. In the future, therapies that involve the suprachoroidal space may take a prominent place in our armamentarium, providing a new opportunity to improve patient care and clinical outcomes across a spectrum of retinal diseases.

Sara V. Branson, BS, is a medical student at Wake Forest University School of Medicine in Winston-Salem, N.C. She has no conflicts of interests to disclose.

Claudia G. Hooten, MD, is a vitreoretinal fellow at Wake Forest Eye Center in Winston-Salem, N.C. She has no conflicts of interest to disclose. Dr. Hooten may be reached at chooten@wakehealth.edu.

Shree K. Kurup, MD, is the director of research and an associate professor of ophthalmology at Wake Forest University Eye Center in Winston-Salem, N.C. He states that he is a consultant for and/or on the advisory board/steering committee of Abbott, AbbVie, Allergan, Clearside Biomedical, Regeneron, and Xoma. Dr. Kurup may be reached at skurup@wakehealth.edu.